You have been on tirzepatide for weeks. You are eating less. The scale has barely moved, or has not moved at all. You are wondering whether the medication is working, or whether you should quit.
Most of the time, the answer is not that the medication is failing. It is one of a small set of fixable things: where you are on the dose ladder, how much you are actually eating, what other medications you take, how you are sleeping, or the simple fact that the weight-loss curve flattens after the first few months, or the natural flattening of the weight-loss curve that occurs after months 4 to 6. Below are 8 honest reasons the scale stalls on compounded tirzepatide, what to do about each, and how to tell when it is time to message the Sunlight care team about your dose.
Key takeaways
- Real weight loss on tirzepatide usually starts in weeks 5 to 12, after the dose climbs above the 2.5 mg starter step.
- By week 12 to 16 at 5 mg or higher, most people see at least 3 to 5 percent body weight loss. If you have not, one of the 8 reasons below probably applies.
- Dose changes on the Sunlight platform run through the patient portal. A licensed clinician reviews your request. The care team coordinates the rest.
- A plateau at month 5 is usually the curve flattening, not the drug failing. The fix is to check that the calorie deficit is still real and to think about whether a dose step up is appropriate.
First, check the timeline
Tirzepatide is dosed in a step ladder. Most people start at 2.5 mg once weekly for the first 4 weeks. That dose is set for tolerance, not for the most weight loss. Real, visible weight loss usually starts once the dose climbs into the 5 to 10 mg range. That is usually weeks 5 through 12 of the program.
In the SURMOUNT-1 trial of FDA-approved tirzepatide, average body weight loss reached 20.9 percent at 72 weeks on the 15 mg dose. The steepest drop happened in months 3 through 9. The curve flattened after that. These numbers assume trial-level adherence and the protocol’s dose schedule. Real-world results are often lower. In practical terms: if you are 3 or 4 weeks in at the 2.5 mg starter step and the scale has not moved, that is the expected pattern, not a failed medication.
A useful threshold to remember: by week 12 to 16 at 5 mg or higher, most people see at least 3 to 5 percent body weight loss. If you have crossed that mark and the scale is still flat, the rest of this article is for you.
8 honest reasons the scale isn't moving on tirzepatide
The next 8 reasons cover about 90 percent of why progress stalls on tirzepatide. Read each, see which ones fit your situation, then work through the 4-step check below.
- You haven’t been at a working dose long enough
- Your dose is too low for your body
- Calorie creep, even with a smaller appetite
- Protein is too low, so you are losing muscle instead of fat
- Sleep, alcohol, and stress are blunting the effect
- Another medication is fighting the medication
- An underlying medical condition is slowing things down
- You have hit a plateau, and that is the curve, not the wall
1. You haven’t been at a working dose long enough
Tirzepatide is usually advanced 2.5 mg, then 5, then 7.5, then 10, then 12.5, then 15 mg weekly. Each step lasts about 4 weeks. People who quit at week 6 because the medication has “stopped working” are usually still in the tolerance-titration phase, not the fat-loss phase. The earliest doses exist to let the gut adjust, not to drive the scale down.
Count the weeks you have been at 5 mg or higher. If it has been less than 8 weeks, you have not actually started the part of the curve where weight loss adds up. The right move is to stay the course and keep working through the dose ladder. If you are unsure how to draw the right dose at your current step, the help-center walkthrough covers it.
2. Your dose is too low for your body
A quiet truth that most troubleshooting articles skip: some people need 10, 12.5, or 15 mg to see real results. The 5 mg “starter therapeutic” dose is not universal. Body weight, insulin sensitivity, and how your body’s GLP-1/GIP receptors respond all shift where the working dose lands.
In the SURMOUNT-1 dose-response data of FDA-approved tirzepatide, weight loss at 15 mg averaged 20.9 percent over 72 weeks. At 5 mg it averaged 15.0 percent. On average, higher doses produced meaningfully more weight loss.
This is where the Sunlight care team comes in. If you have been at 5 mg for 8 or more weeks with no movement, message the Sunlight care team through the patient portal. A licensed clinician on the Sunlight platform can review whether a dose increase is appropriate based on your tolerance, your starting weight, and your medical history. Dose changes happen inside the program, not outside it.
3. Calorie creep, even with a smaller appetite
The trap on tirzepatide is that the medication quiets hunger. So it is easy to assume you are automatically in a calorie deficit. Often, you are not. Three things show up over and over:
- Liquid calories. A 16 oz oat-milk latte, a glass of wine, a beer, a fruit smoothie. Each one is 200 to 400 calories that does not register as “eating.”
- Grazing. A handful of nuts. A bite of pasta off a partner’s plate. A square of dark chocolate. Small portions feel like nothing. Added up across a day, they outpace the appetite suppression.
- High-density “small” portions. Nut butter, oils, salad dressings, cheese. A tablespoon of olive oil is 120 calories. A small handful of almonds is 200.
A 2023 lifestyle subanalysis in the New England Journal of Medicine found that patients who added structured food tracking to GLP-1 therapy lost an extra 21.1 percent body weight over 12 weeks compared with medication alone. The point is not to count macros forever. It is to log 5 days of food honestly and see the actual pattern. Most people are surprised. For Sunlight patients specifically, the first-week eating guide covers the most common dietary patterns that slow early progress.
4. Protein is too low, so you are losing muscle instead of fat
A useful target: 0.7 to 1.0 grams of protein per pound of your goal body weight per day. For a 200 lb patient with a goal of 170 lbs, that is about 120 to 170 grams of protein per day.
Why it matters: a smaller appetite plus low protein equals muscle loss. Muscle loss lowers your resting metabolism. That makes long-term loss harder. The scale moves, but the body composition is wrong, and progress stalls sooner.
Load up on protein at breakfast, when appetite is highest. Add a whey or pea-protein shake mid-day if needed. Pick protein over carbs at every meal. Some anchors: 4 oz cooked chicken is about 35 g of protein, 6 oz of Greek yogurt is typically closer to 15 to 17 g depending on brand, a scoop of whey is 25 g, three eggs are 18 g.
5. Sleep, alcohol, and stress are blunting the effect
Specific numbers, not platitudes:
- Sleep. According to the Mayo Clinic and a 2010 study in the Annals of Internal Medicine, sleeping less than 6 hours a night raises ghrelin, the hunger hormone, and lowers leptin, the fullness signal. People who routinely undersleep often plateau even at the right dose.
- Alcohol. A 6 oz pour of wine is about 150 calories. Two drinks a night is about 300 calories of zero-protein, zero-fullness calories. Plus broken sleep. Plus next-morning hunger.
- Stress. Chronic cortisol shifts fat storage toward the belly and raises insulin resistance, per the Mayo Clinic. Stress eating is real, but the hormone effect alone moves the needle.
Pick one to fix this week. Sleep is usually the highest-leverage lever. Aim for 7 or more hours, consistently, before changing anything else.
6. Another medication is fighting the medication
Several types of medication can cause weight gain or blunt your response to GLP-1 therapy. The Mayo Clinic and Cleveland Clinic both publish lists. The most common:
- Corticosteroids (prednisone, dexamethasone)
- Some antidepressants (SSRIs like paroxetine, tricyclics like amitriptyline, and mirtazapine)
- Beta blockers (propranolol, metoprolol)
- Antipsychotics (olanzapine, risperidone, quetiapine)
- Insulin and sulfonylureas in people with type 2 diabetes
- Some seizure medications (valproate, gabapentin)
- Some hormonal birth control, in some patients
Do not stop any of these without a clinician. Many are necessary. The action is to pull up your medication list. If anything on it falls into these categories, message the Sunlight care team. A licensed clinician can review whether a tirzepatide dose change or a separate conversation with your primary care doctor is appropriate.
7. An underlying medical condition is slowing things down
According to the Mayo Clinic, several common conditions slow weight loss on their own:
- Hypothyroidism. Low thyroid hormone slows your resting metabolism. Symptoms include fatigue, cold intolerance, dry skin, and hair changes.
- PCOS. Insulin resistance and high androgens slow fat loss, especially around the middle.
- Cushing’s syndrome. Long-term high cortisol, often missed because symptoms look like stress and weight gain.
- Undiagnosed insulin resistance. Even without a formal diabetes diagnosis, it slows the body’s response to GLP-1 therapy.
Aging and perimenopause or menopause also shift hormone patterns and slow weight loss for many women. If you have unexplained fatigue, cold intolerance, irregular cycles, or hair changes alongside a stalled scale, ask the Sunlight care team about screening labs. A licensed clinician can decide whether more workup is appropriate.
A note on thyroid history: tirzepatide carries a boxed warning for thyroid C-cell tumor risk based on rodent studies. It should not be used by patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). If either applies to you, raise it with the Sunlight care team before any dose change.
8. You have hit a plateau, and that is the curve, not the wall
Plateaus get treated as failure. Most of the time they are just math.
In the SURMOUNT-1 trial of FDA-approved tirzepatide, weight loss continued through 72 weeks. But the curve flattened after months 4 to 6. The body adapts. Your resting metabolism resets at the new, lower weight. Each pound lost takes slightly fewer calories to maintain. So the same deficit produces a smaller weekly drop. The curve flattens, but the trend is still down.
Two things matter at this point. First, check that you are still in a real deficit (see reason #3). Second, think about whether the dose needs to step up to push through the new set point.
The check: weigh on the same scale, at the same time of day, for 7 days in a row. Compare this week’s 7-day average to the previous month’s 7-day average. If the trend line is still down, you are not plateaued. You are inside the curve. If the average is flat for 4 or more weeks at a working dose, that is when the dose conversation makes sense.
What to do next: a 4-step check
Before you message the care team, run a quick check on yourself. Each step is short. Most people land an answer in a week or two.
- This week, log 5 days of food honestly. No judgment. No perfect macros. Just the data. Pay attention to liquid calories and grazing.
- This week, pull up your current medication list. Check it against the 7 categories named in reason #6. Flag anything that overlaps.
- Next week, pick one lifestyle lever and run it for 14 days. Sleep, alcohol, or protein. One change at a time so you know what moved the needle. Re-weigh at day 14 with a 7-day average.
- After 14 to 30 days, if the scale still has not moved, message the Sunlight care team. Include your current weekly dose, how many weeks at that dose, your 7-day weight average, any side effects, your food-log summary, and any medications you suspect might be a factor. A licensed clinician will review your request and respond.
The Sunlight platform is built for this kind of mid-program adjustment. The care team and a licensed clinician are the path, not a phone call to an outside clinic and not a quiet decision to quit.
When (and how) to talk to your care team about your dose
Dose changes on the Sunlight platform run through the patient portal. The care team handles your message. A licensed clinician on the platform, licensed in your state, reviews your case. If a change is appropriate, the next prescription is adjusted. No outside appointment, no need to restart the intake process from scratch.
When to message:
- You have been at 5 mg or higher for 8 or more weeks with no weight movement.
- You have hit a 4-plus-week plateau at a working dose after real early loss.
- Side effects from your current dose have settled and a step up may be tolerable.
- You are unsure whether one of the 8 reasons above applies to you and want a second look from a clinician.
What to include in the message:
- Current weekly dose (e.g., “5 mg, weekly, every Sunday”)
- Number of weeks at the current dose
- Your 7-day weight average and how it compares with the prior month
- Any side effects, and whether they have settled
- Notes from the 4-step check above (food log, medications, sleep)
What happens next: a licensed clinician on the Sunlight platform reviews the request. If a dose change is appropriate, the clinician approves it. The Sunlight care team coordinates the next shipment from the compounding pharmacy. The setup is built to be low-friction. The whole point of the program is that mid-program changes do not require starting over.
What if you are a true non-responder?
A small group of GLP-1 patients are clinical non-responders. The published literature defines this as less than 5 percent body weight loss after 6 months at a working dose with reasonable lifestyle alignment. Non-responders make up about 9 percent of GLP-1 patients in the STEP-1 follow-up analyses published in the New England Journal of Medicine.
This is not a judgment about effort. It is a known biological variation in how GLP-1 and GIP signaling work across different bodies.
If you think you are in this group, three productive next steps:
- Confirm with the care team that you have really been at a working dose long enough. Many people who think they are non-responders are still under-dosed.
- Ask whether switching to a different medication is appropriate. Some people respond differently to compounded semaglutide than to compounded tirzepatide. The tirzepatide vs. semaglutide comparison covers the differences in mechanism and reported outcomes. A licensed clinician on the Sunlight platform can make the call.
- Talk about whether peptide add-ons might support metabolic recovery alongside the GLP-1. Compounded NAD+ is one option Sunlight patients sometimes add, clinician-reviewed, alongside the GLP-1 program. The NAD+ with GLP-1 overview covers the details.
Whatever the path, the decision runs through the Sunlight care team and a licensed clinician. Do not switch molecules on your own. Do not abandon the program before that conversation has happened.
Frequently asked questions
How long does it take for tirzepatide to start working?
What dose of tirzepatide is best for weight loss?
Do I need to be in a calorie deficit on tirzepatide?
Why has tirzepatide stopped working after a few months?
Can other medications make tirzepatide stop working?
Compounded tirzepatide is not FDA-approved. It is dispensed by state-licensed compounding pharmacies and requires a prescription from a licensed clinician. Individual results may vary.
References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).” New England Journal of Medicine 2022;387:205-216.
- Aronne LJ, Sattar N, Horn DB, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).” New England Journal of Medicine May 2025.
- Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1).” New England Journal of Medicine 2021;384:989-1002.
- Mayo Clinic. “Prescription weight-loss drugs.” Last reviewed 2024.
- Cleveland Clinic. “Medications that cause weight gain.”
- Nedeltcheva AV et al. “Insufficient Sleep Undermines Dietary Efforts to Reduce Adiposity.” Annals of Internal Medicine 2010;153:435-441.